Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04450069 · ClinicalTrials.gov registry record · Phase 1
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies
A Phase 1 study of Mantle Cell Lymphoma and Waldenstrom Macroglobulinemia, sponsored by Calibr, a division of Scripps Research.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 8
- Study locations
NCT04450069 is a Phase 1 study of Mantle Cell Lymphoma and Waldenstrom Macroglobulinemia that has completed, run by Calibr, a division of Scripps Research. The registered enrollment target is 18 participants, below the 104-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (83% lower). The trial reports 8 study locations across 7 states.
The verdict
NCT04450069, a Phase 1 study of Mantle Cell Lymphoma and Waldenstrom Macroglobulinemia, has completed, sponsored by Calibr, a division of Scripps Research.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 8
- Study locations
Study Summary
CLBR001 + SWI019 is an combination investigational immunotherapy being evaluated as a potential treatment for patients diagnosed with B cell malignancies who are refractory or unresponsive to salvage therapy or who cannot be considered for or have progressed after autologous hematopoietic cell transplantation. This first-in-human study will assess the safety and tolerability of CLBR001 + SWI019 and is designed to determine the maximum tolerated dose (MTD) or optimal SWI019 dose (OSD). Patients will be administered a single infusion of CLBR001 cells followed by cycles of SWI019. The study will also assess the pharmacokinetics and pharmacodynamics of CLBR001 + SWI019.
Conditions Studied
Interventions
- COMBINATION_PRODUCT CLBR001 and SWI019
Study Locations (8)
California
- City of Hope National Medical Center - Duarte
- University of California at San Diego - San Diego
Illinois
- University of Chicago - Chicago
Minnesota
- Masonic Cancer Center, University of Minnesota - Minneapolis
New York
- Weill Cornell Medical College - New York Presbyterian Hospital - New York
North Carolina
- Wake Forest Baptist Health - Winston-Salem
Tennessee
- Sarah Cannon Research Institute - Tennessee Oncology - Nashville
Texas
- Sarah Cannon Research Institute - Texas Transplant Institute - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2020-08-14 |
| Est. Completion | 2024-05-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04450069
The ClinicalTrials.gov registry entry for NCT04450069 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 104-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (83% lower). The listed sponsor is Calibr, a division of Scripps Research, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Mantle Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which CLBR001 and SWI019 is the first listed.
NCT04450069 reports 8 study locations spanning 7 distinct geographic areas - top geographies include California, Illinois, Minnesota.
Frequently Asked Questions
What is clinical trial NCT04450069 about?
NCT04450069 is a clinical study titled "CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies". CLBR001 + SWI019 is an combination investigational immunotherapy being evaluated as a potential treatment for patients diagnosed with B cell malignancies who are refractory or unresponsive to salvage therapy or who cannot be considered for or have progressed after autologous hematopoietic cell trans...
What is the current status of trial NCT04450069?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2020-08-14. Estimated completion is 2024-05-06.
What conditions does trial NCT04450069 study?
This clinical trial studies the following conditions: Mantle Cell Lymphoma, Waldenstrom Macroglobulinemia, Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Primary Mediastinal Large B Cell Lymphoma.
What interventions are being tested in trial NCT04450069?
The interventions under investigation include: CLBR001 and SWI019 (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04450069?
This trial is sponsored by Calibr, a division of Scripps Research, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04450069 being conducted?
This trial has 8 study locations across California, Illinois, Minnesota, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mantle Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 1
-
A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma
RECRUITING · Phase 1
-
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
RECRUITING · Phase 1
-
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.